Golabi, P.; Fazel, S.; Otgonsuren, M.; Sayiner, M.; Locklear, C.T.; Younossi, Z.M. Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities. Medicine, 2017, 96(9), e5904.
[http://dx.doi.org/10.1097/MD.0000000000005904] [PMID: 28248853]

Marrero, J.A.; Kulik, L.M.; Sirlin, C.B.; Zhu, A.X.; Finn, R.S.; Abecassis, M.M.; Roberts, L.R.; Heimbach, J.K. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 Practice guidance by the American Association for the study of liver diseases. Hepatology, 2018, 68(2), 723-750.
[http://dx.doi.org/10.1002/hep.29913] [PMID: 29624699]

Tzartzeva, K.; Obi, J.; Rich, N.E.; Parikh, N.D.; Marrero, J.A.; Yopp, A.; Waljee, A.K.; Singal, A.G. Surveillance imaging and alpha feto-protein for early detection of hepatocellular carcinoma in patients with cirrhosis: A meta-analysis. Gastroenterology, 2018, 154(6), 1706-1718.
[http://dx.doi.org/10.1053/j.gastro.2018.01.064] [PMID: 29425931]

Attwa, M.H.; El-Etreby, S.A. Guide for diagnosis and treatment of hepatocellular carcinoma. World J. Hepatol., 2015, 7(12), 1632-1651.
[http://dx.doi.org/10.4254/wjh.v7.i12.1632] [PMID: 26140083]

Wang, W.; Wei, C. Advances in the early diagnosis of hepatocellular carcinoma. Genes Dis., 2020, 7(3), 308-319.
[http://dx.doi.org/10.1016/j.gendis.2020.01.014] [PMID: 32884985]

Heidrich, I.; Ačkar, L.; Mossahebi, M.P.; Pantel, K. Liquid biopsies: Potential and challenges. Int. J. Cancer, 2021, 148(3), 528-545.
[http://dx.doi.org/10.1002/ijc.33217] [PMID: 32683679]

Ryu, J.S.; Lim, J.H.; Lee, M.K.; Lee, S.J.; Kim, H.J.; Kim, M.J.; Park, M.H.; Kim, J.S.; Nam, H.S.; Park, N.; Yong, S.J. Feasibility of bronchial washing fluid-based approach to early-stage lung cancer diagnosis. Oncologist, 2019, 24(7), e603-e606.
[http://dx.doi.org/10.1634/theoncologist.2019-0147] [PMID: 31036768]

Keller, L.; Belloum, Y.; Wikman, H.; Pantel, K. Clinical relevance of blood-based ctDNA analysis: Mutation detection and beyond. Br. J. Cancer, 2021, 124(2), 345-358.
[http://dx.doi.org/10.1038/s41416-020-01047-5] [PMID: 32968207]

Yan, L.; Chen, Y.; Zhou, J.; Zhao, H.; Zhang, H.; Wang, G. Diagnostic value of circulating cell-free DNA levels for hepatocellular carcinoma. Int. J. Infect. Dis., 2018, 67, 92-97.
[http://dx.doi.org/10.1016/j.ijid.2017.12.002] [PMID: 29229500]

Jiang, P.; Chan, C.W.M.; Chan, K.C.A.; Cheng, S.H.; Wong, J.; Wong, V.W.S.; Wong, G.L.H.; Chan, S.L.; Mok, T.S.K.; Chan, H.L.Y.; Lai, P.B.S.; Chiu, R.W.K.; Lo, Y.M.D. Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients. Proc. Natl. Acad. Sci., 2015, 112(11), E1317-E1325.
[http://dx.doi.org/10.1073/pnas.1500076112] [PMID: 25646427]

Zhang, X.; Wang, Z.; Tang, W.; Wang, X.; Liu, R.; Bao, H.; Chen, X.; Wei, Y.; Wu, S.; Bao, H.; Wu, X.; Shao, Y.; Fan, J.; Zhou, J. Ultra-sensitive and affordable assay for early detection of primary liver cancer using plasma cell‐free DNA fragmentomics. Hepatology, 2022, 76(2), 317-329.
[http://dx.doi.org/10.1002/hep.32308] [PMID: 34954829]

Marchio, A.; Amougou Atsama, M.; Béré, A.; Komas, N.P.; Noah Noah, D.; Atangana, P.J.A.; Camengo-Police, S.M.; Njouom, R.; Bekondi, C.; Pineau, P. Droplet digital PCR detects high rate of TP53 R249S mutants in cell-free DNA of middle African patients with hepatocellular carcinoma. Clin. Exp. Med., 2018, 18(3), 421-431.
[http://dx.doi.org/10.1007/s10238-018-0502-9] [PMID: 29749584]

Akuta, N.; Kawamura, Y.; Kobayashi, M.; Arase, Y.; Saitoh, S.; Fujiyama, S.; Sezaki, H.; Hosaka, T.; Kobayashi, M.; Suzuki, Y.; Suzuki, F.; Ikeda, K.; Kumada, H. TERT promoter mutation in serum cell-free DNA is a diagnostic marker of primary hepatocellular carcinoma in patients with nonalcoholic fatty liver disease. Oncology, 2021, 99(2), 114-123.
[http://dx.doi.org/10.1159/000510366] [PMID: 32998139]

Kaseb, A.O.; Sánchez, N.S.; Sen, S.; Kelley, R.K.; Tan, B.; Bocobo, A.G.; Lim, K.H.; Abdel-Wahab, R.; Uemura, M.; Pestana, R.C.; Qiao, W.; Xiao, L.; Morris, J.; Amin, H.M.; Hassan, M.M.; Rashid, A.; Banks, K.C.; Lanman, R.B.; Talasaz, A.; Mills-Shaw, K.R.; George, B.; Haque, A.; Raghav, K.P.S.; Wolff, R.A.; Yao, J.C.; Meric-Bernstam, F.; Ikeda, S.; Kurzrock, R. Molecular profiling of hepatocellular carcinoma using circulating cell-Free DNA. Clin. Cancer Res., 2019, 25(20), 6107-6118.
[http://dx.doi.org/10.1158/1078-0432.CCR-18-3341] [PMID: 31363003]

Guo, W.; Lu, J.; Yan, L.; Sun, D.; Gong, L.; Shi, W. Molecular alterations of circulating cell-free DNA in the pathological progression of hepatocellular carcinoma. J. Oncol., 2021, 2021, 1-8.
[http://dx.doi.org/10.1155/2021/3637436] [PMID: 34899905]

Zheng, B.; Liu, X.L.; Fan, R.; Bai, J.; Wen, H.; Du, L.T.; Jiang, G.Q.; Wang, C.Y.; Fan, X.T.; Ye, Y.N.; Qian, Y.S.; Wang, Y.C.; Liu, G.J.; Deng, G.H.; Shen, F.; Hu, H.P.; Wang, H.; Zhang, Q.Z.; Ru, L.L.; Zhang, J.; Gao, Y.H.; Xia, J.; Yan, H.D.; Liang, M.F.; Yu, Y.L.; Sun, F.M.; Gao, Y.J.; Sun, J.; Zhong, C.X.; Wang, Y.; Kong, F.; Chen, J.M.; Zheng, D.; Yang, Y.; Wang, C.X.; Wu, L.; Hou, J.L.; Liu, J.F.; Wang, H.Y.; Chen, L. The landscape of cell-free HBV integrations and mutations in cirrhosis and hepatocellular carcinoma patients. Clin. Cancer Res., 2021, 27(13), 3772-3783.
[http://dx.doi.org/10.1158/1078-0432.CCR-21-0002] [PMID: 33947693]

Qu, C.; Wang, Y.; Wang, P.; Chen, K.; Wang, M.; Zeng, H.; Lu, J.; Song, Q.; Diplas, B.H.; Tan, D.; Fan, C.; Guo, Q.; Zhu, Z.; Yin, H.; Jiang, L.; Chen, X.; Zhao, H.; He, H.; Wang, Y.; Li, G.; Bi, X.; Zhao, X.; Chen, T.; Tang, H.; Lv, C.; Wang, D.; Chen, W.; Zhou, J.; Zhao, H.; Cai, J.; Wang, X.; Wang, S.; Yan, H.; Zeng, Y.X.; Cavenee, W.K.; Jiao, Y. Detection of early-stage hepatocellular carcinoma in asymptomatic HBsAg-seropositive individuals by liquid biopsy. Proc. Natl. Acad. Sci., 2019, 116(13), 6308-6312.
[http://dx.doi.org/10.1073/pnas.1819799116] [PMID: 30858324]

Jiang, P.; Sun, K.; Tong, Y.K.; Cheng, S.H.; Cheng, T.H.T.; Heung, M.M.S.; Wong, J.; Wong, V.W.S.; Chan, H.L.Y.; Chan, K.C.A.; Lo, Y.M.D.; Chiu, R.W.K. Preferred end coordinates and somatic variants as signatures of circulating tumor DNA associated with hepatocellular carcinoma. Proc. Natl. Acad. Sci., 2018, 115(46), E10925-E10933.
[http://dx.doi.org/10.1073/pnas.1814616115] [PMID: 30373822]

Jin, C.; Liu, X.; Zheng, W.; Su, L.; Liu, Y.; Guo, X.; Gu, X.; Li, H.; Xu, B.; Wang, G.; Yu, J.; Zhang, Q.; Bao, D.; Wan, S.; Xu, F.; Lai, X.; Liu, J.; Xing, J. Characterization of fragment sizes, copy number aberrations and 4‐mer end motifs in cell‐free DNA of hepatocellular carcinoma for enhanced liquid biopsy‐based cancer detection. Mol. Oncol., 2021, 15(9), 2377-2389.
[http://dx.doi.org/10.1002/1878-0261.13041] [PMID: 34133846]

Tao, K.; Bian, Z.; Zhang, Q.; Guo, X.; Yin, C.; Wang, Y.; Zhou, K.; Wan, S.; Shi, M.; Bao, D.; Yang, C.; Xing, J. Machine learning-based genome-wide interrogation of somatic copy number aberrations in circulating tumor DNA for early detection of hepatocellular carcinoma. EBioMedicine, 2020, 56, 102811.
[http://dx.doi.org/10.1016/j.ebiom.2020.102811] [PMID: 32512514]

Meng, Z.; Ren, Q.; Zhong, G.; Li, S.; Chen, Y.; Wu, W.; Feng, Y.; Mao, M.; Zhang, F.; Long, G. Noninvasive detection of hepatocellular carcinoma with circulating tumor DNA features and α-fetoprotein. J. Mol. Diagn., 2021, 23(9), 1174-1184.
[http://dx.doi.org/10.1016/j.jmoldx.2021.06.003] [PMID: 34182124]

Cohen, J.D.; Li, L.; Wang, Y.; Thoburn, C.; Afsari, B.; Danilova, L.; Douville, C.; Javed, A.A.; Wong, F.; Mattox, A.; Hruban, R.H.; Wolf-gang, C.L.; Goggins, M.G.; Dal Molin, M.; Wang, T.L.; Roden, R.; Klein, A.P.; Ptak, J.; Dobbyn, L.; Schaefer, J.; Silliman, N.; Popoli, M.; Vogelstein, J.T.; Browne, J.D.; Schoen, R.E.; Brand, R.E.; Tie, J.; Gibbs, P.; Wong, H.L.; Mansfield, A.S.; Jen, J.; Hanash, S.M.; Falconi, M.; Allen, P.J.; Zhou, S.; Bettegowda, C.; Diaz, L.A., Jr; Tomasetti, C.; Kinzler, K.W.; Vogelstein, B.; Lennon, A.M.; Papadopoulos, N. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science, 2018, 359(6378), 926-930.
[http://dx.doi.org/10.1126/science.aar3247] [PMID: 29348365]

Lennon, A.M.; Buchanan, A.H.; Kinde, I.; Warren, A.; Honushefsky, A.; Cohain, A.T.; Ledbetter, D.H.; Sanfilippo, F.; Sheridan, K.; Rosica, D.; Adonizio, C.S.; Hwang, H.J.; Lahouel, K.; Cohen, J.D.; Douville, C.; Patel, A.A.; Hagmann, L.N.; Rolston, D.D.; Malani, N.; Zhou, S.; Bettegowda, C.; Diehl, D.L.; Urban, B.; Still, C.D.; Kann, L.; Woods, J.I.; Salvati, Z.M.; Vadakara, J.; Leeming, R.; Bhattacharya, P.; Walter, C.; Parker, A.; Lengauer, C.; Klein, A.; Tomasetti, C.; Fishman, E.K.; Hruban, R.H.; Kinzler, K.W.; Vogelstein, B.; Papadopoulos, N. Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention. Science, 2020, 369(6499), eabb9601.
[http://dx.doi.org/10.1126/science.abb9601] [PMID: 32345712]

Oussalah, A.; Rischer, S.; Bensenane, M.; Conroy, G.; Filhine-Tresarrieu, P.; Debard, R.; Forest-Tramoy, D.; Josse, T.; Reinicke, D.; Garcia, M.; Luc, A.; Baumann, C.; Ayav, A.; Laurent, V.; Hollenbach, M.; Ripoll, C.; Guéant-Rodriguez, R.M.; Namour, F.; Zipprich, A.; Fleischhacker, M.; Bronowicki, J.P.; Guéant, J.L. Plasma mSEPT9: A novel circulating cell-free DNA-based epigenetic biomarker to diagnose hepatocellular carcinoma. EBioMedicine, 2018, 30, 138-147.
[http://dx.doi.org/10.1016/j.ebiom.2018.03.029] [PMID: 29627389]

Li, B.; Huang, H.; Huang, R.; Zhang, W.; Zhou, G.; Wu, Z.; Lv, C.; Han, X.; Jiang, L.; Li, Y.; Li, B.; Zhang, Z. SEPT9 Gene methylation as a noninvasive marker for hepatocellular carcinoma. Dis. Markers, 2020, 2020, 1-9.
[http://dx.doi.org/10.1155/2020/6289063] [PMID: 33178361]

Wu, H.C.; Yang, H.I.; Wang, Q.; Chen, C.J.; Santella, R.M. Plasma DNA methylation marker and hepatocellular carcinoma risk prediction model for the general population. Carcinogenesis, 2017, 38(10), 1021-1028.
[http://dx.doi.org/10.1093/carcin/bgx078] [PMID: 28981677]

Shen, J; Wang, S; Zhang, YJ; Kappil, M; Wu, HC; Kibriya, MG; Wang, Q; Jasmine, F; Ahsan, H; Lee, PH; Yu, MW; Chen, CJ; Santella, RM. Ge-nome-wide DNA methylation profiles in hepatocellular carcinoma. Hepatology., 2012, 55(6), 1799-1808.
[http://dx.doi.org/10.1002/hep.25569.] [PMID: 22234943] [http://dx.doi.org/10.3892/or.2016.4619] [PMID: 26883180]

Holmila, R.; Sklias, A.; Muller, D.C.; Degli, E.D.; Guilloreau, P.; Mckay, J.; Sangrajrang, S.; Srivatanakul, P.; Hainaut, P.; Merle, P.; Herceg, Z.; Nogueira da Costa, A. Targeted deep sequencing of plasma circulating cell-free DNA reveals Vimentin and Fibulin 1 as potential epigenetic biomarkers for hepatocellular carcinoma. PLoS One, 2017, 12(3), e0174265.
[http://dx.doi.org/10.1371/journal.pone.0174265] [PMID: 28333958]

Xu, R.; Wei, W.; Krawczyk, M.; Wang, W.; Luo, H.; Flagg, K.; Yi, S.; Shi, W.; Quan, Q.; Li, K.; Zheng, L.; Zhang, H.; Caughey, B.A.; Zhao, Q.; Hou, J.; Zhang, R.; Xu, Y.; Cai, H.; Li, G.; Hou, R.; Zhong, Z.; Lin, D.; Fu, X.; Zhu, J.; Duan, Y.; Yu, M.; Ying, B.; Zhang, W.; Wang, J.; Zhang, E.; Zhang, C.; Li, O.; Guo, R.; Carter, H.; Zhu, J.; Hao, X.; Zhang, K. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. Nat. Mater., 2017, 16(11), 1155-1161.
[http://dx.doi.org/10.1038/nmat4997] [PMID: 29035356]

Kisiel, J.B.; Dukek, B.A.; V S R Kanipakam, R.; Ghoz, H.M.; Yab, T.C; Berger, C.K.; Taylor, W.R.; Foote, P.H.; Giama, N.H.; Onyirioha, K.; Abdallah, M.A.; Burger, K.N.; Slettedahl, S.W.; Mahoney, D.W.; Smyrk, T.C.; Lewis, J.T.; Giakoumopoulos, M.; Allawi, H.T.; Lidgard, G.P.; Roberts, L.R.; Ahlquist, D.A. Hepatocellular Carcinoma detection by plasma methylated DNA: Discovery, phase I pilot, and phase II clinical validation. Hepatology, 2019, 69(3), 1180-1192.
[http://dx.doi.org/10.1002/hep.30244] [PMID: 30168613]

Chalasani, N.P.; Ramasubramanian, T.S.; Bhattacharya, A.; Olson, M.C.; Edwards V, D.K.; Roberts, L.R.; Kisiel, J.B.; Reddy, K.R.; Lidgard, G.P.; Johnson, S.C.; Bruinsma, J.J. A novel blood-based panel of methylated DNA and protein markers for detection of early-stage hepatocellular carcinoma. Clin. Gastroenterol. Hepatol., 2021, 19(12), 2597-2605.e4.
[http://dx.doi.org/10.1016/j.cgh.2020.08.065] [PMID: 32889146]

Chen, X.; Gole, J.; Gore, A.; He, Q.; Lu, M.; Min, J.; Yuan, Z.; Yang, X.; Jiang, Y.; Zhang, T.; Suo, C.; Li, X.; Cheng, L.; Zhang, Z.; Niu, H.; Li, Z.; Xie, Z.; Shi, H.; Zhang, X.; Fan, M.; Wang, X.; Yang, Y.; Dang, J.; McConnell, C.; Zhang, J.; Wang, J.; Yu, S.; Ye, W.; Gao, Y.; Zhang, K.; Liu, R.; Jin, L. Non-invasive early detection of cancer four years before conventional diagnosis using a blood test. Nat. Commun., 2020, 11(1), 3475.
[http://dx.doi.org/10.1038/s41467-020-17316-z] [PMID: 32694610]

Liu, M.C.; Oxnard, G.R.; Klein, E.A.; Swanton, C.; Seiden, M.V.; Liu, M.C.; Oxnard, G.R.; Klein, E.A.; Smith, D.; Richards, D.; Yeatman, T.J.; Cohn, A.L.; Lapham, R.; Clement, J.; Parker, A.S.; Tummala, M.K.; McIntyre, K.; Sekeres, M.A.; Bryce, A.H.; Siegel, R.; Wang, X.; Cosgrove, D.P.; Abu-Rustum, N.R.; Trent, J.; Thiel, D.D.; Becerra, C.; Agrawal, M.; Garbo, L.E.; Giguere, J.K.; Michels, R.M.; Harris, R.P.; Richey, S.L.; McCarthy, T.A.; Waterhouse, D.M.; Couch, F.J.; Wilks, S.T.; Krie, A.K.; Balaraman, R.; Restrepo, A.; Meshad, M.W.; Rieger-Christ, K.; Sullivan, T.; Lee, C.M.; Greenwald, D.R.; Oh, W.; Tsao, C-K.; Fleshner, N.; Kennecke, H.F.; Khalil, M.F.; Spigel, D.R.; Manhas, A.P.; Ulrich, B.K.; Kovoor, P.A.; Stokoe, C.; Courtright, J.G.; Yimer, H.A.; Larson, T.G.; Swanton, C.; Seiden, M.V.; Cummings, S.R.; Absalan, F.; Alexander, G.; Allen, B.; Amini, H.; Aravanis, A.M.; Bagaria, S.; Bazargan, L.; Beausang, J.F.; Berman, J.; Betts, C.; Blocker, A.; Bredno, J.; Calef, R.; Cann, G.; Carter, J.; Chang, C.; Chawla, H.; Chen, X.; Chien, T.C.; Civello, D.; Davydov, K.; Demas, V.; Desai, M.; Dong, Z.; Fayzullina, S.; Fields, A.P.; Filippova, D.; Freese, P.; Fung, E.T.; Gnerre, S.; Gross, S.; Halks-Miller, M.; Hall, M.P.; Hartman, A-R.; Hou, C.; Hubbell, E.; Hunkapiller, N.; Jagadeesh, K.; Jamshidi, A.; Jiang, R.; Jung, B.; Kim, T.H.; Klausner, R.D.; Kurtzman, K.N.; Lee, M.; Lin, W.; Lipson, J.; Liu, H.; Liu, Q.; Lopatin, M.; Maddala, T.; Maher, M.C.; Melton, C.; Mich, A.; Nautiyal, S.; Newman, J.; Newman, J.; Nicula, V.; Nicolaou, C.; Nikolic, O.; Pan, W.; Patel, S.; Prins, S.A.; Rava, R.; Ronaghi, N.; Sakarya, O.; Satya, R.V.; Schellenberger, J.; Scott, E.; Sehnert, A.J.; Shaknovich, R.; Shanmugam, A.; Shashidhar, K.C.; Shen, L.; Shenoy, A.; Shojaee, S.; Singh, P.; Steffen, K.K.; Tang, S.; Toung, J.M.; Valouev, A.; Venn, O.; Williams, R.T.; Wu, T.; Xu, H.H.; Yakym, C.; Yang, X.; Yecies, J.; Yip, A.S.; Youngren, J.; Yue, J.; Zhang, J.; Zhang, L.; Zhang, L.Q.; Zhang, N.; Curtis, C.; Berry, D.A. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann. Oncol., 2020, 31(6), 745-759.
[http://dx.doi.org/10.1016/j.annonc.2020.02.011] [PMID: 33506766]

Cai, J.; Chen, L.; Zhang, Z.; Zhang, X.; Lu, X.; Liu, W.; Shi, G.; Ge, Y.; Gao, P.; Yang, Y.; Ke, A.; Xiao, L.; Dong, R.; Zhu, Y.; Yang, X.; Wang, J.; Zhu, T.; Yang, D.; Huang, X.; Sui, C.; Qiu, S.; Shen, F.; Sun, H.; Zhou, W.; Zhou, J.; Nie, J.; Zeng, C.; Stroup, E.K.; Zhang, X.; Chiu, B.C.H.; Lau, W.Y.; He, C.; Wang, H.; Zhang, W.; Fan, J. Genome-wide mapping of 5-hydroxymethylcytosines in circulating cell-free DNA as a non-invasive approach for early detection of hepatocellular carcinoma. Gut, 2019, 68(12), 2195-2205.
[http://dx.doi.org/10.1136/gutjnl-2019-318882] [PMID: 31358576]

Cai, Z.; Zhang, J.; He, Y.; Xia, L.; Dong, X.; Chen, G.; Zhou, Y.; Hu, X.; Zhong, S.; Wang, Y.; Chen, H.; Xie, D.; Liu, X.; Liu, J. Liquid biopsy by combining 5-hydroxymethylcytosine signatures of plasma cell-free DNA and protein biomarkers for diagnosis and prognosis of hepatocellular carcinoma. ESMO Open, 2021, 6(1), 100021.
[http://dx.doi.org/10.1016/j.esmoop.2020.100021] [PMID: 33508734]

Chen, L.; Abou-Alfa, G.K.; Zheng, B.; Liu, J.F.; Bai, J.; Du, L.T.; Qian, Y.S.; Fan, R.; Liu, X.L.; Wu, L.; Hou, J.L.; Wang, H.Y. Genome-scale profiling of circulating cell-free DNA signatures for early detection of hepatocellular carcinoma in cirrhotic patients. Cell Res., 2021, 31(5), 589-592.
[http://dx.doi.org/10.1038/s41422-020-00457-7] [PMID: 33589745]

Pantel, K.; Speicher, M.R. The biology of circulating tumor cells. Oncogene, 2016, 35(10), 1216-1224.
[http://dx.doi.org/10.1038/onc.2015.192] [PMID: 26050619]

Praharaj, P.P.; Bhutia, S.K.; Nagrath, S.; Bitting, R.L.; Deep, G. Circulating tumor cell-derived organoids: Current challenges and promises in medical research and precision medicine. Biochim. Biophys. Acta Rev. Cancer, 2018, 1869(2), 117-127.
[http://dx.doi.org/10.1016/j.bbcan.2017.12.005] [PMID: 29360544]

Tellez-Gabriel, M.; Cochonneau, D.; Cadé, M.; Jubelin, C.; Heymann, M.F.; Heymann, D. Circulating tumor cell-derived pre-clinical models for personalized medicine. Cancers, 2018, 11(1), 19.
[http://dx.doi.org/10.3390/cancers11010019] [PMID: 30586936]

Heitzer, E.; Auer, M.; Gasch, C.; Pichler, M.; Ulz, P.; Hoffmann, E.M.; Lax, S.; Waldispuehl-Geigl, J.; Mauermann, O.; Lackner, C.; Höfler, G.; Eisner, F.; Sill, H.; Samonigg, H.; Pantel, K.; Riethdorf, S.; Bauernhofer, T.; Geigl, J.B.; Speicher, M.R. Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. Cancer Res., 2013, 73(10), 2965-2975.
[http://dx.doi.org/10.1158/0008-5472.CAN-12-4140] [PMID: 23471846]

Vignot, S.; Frampton, G.M.; Soria, J.C.; Yelensky, R.; Commo, F.; Brambilla, C.; Palmer, G.; Moro-Sibilot, D.; Ross, J.S.; Cronin, M.T.; André, F.; Stephens, P.J.; Lazar, V.; Miller, V.A.; Brambilla, E. Next-generation sequencing reveals high concordance of recurrent somatic alterations between primary tumor and metastases from patients with non-small-cell lung cancer. J. Clin. Oncol., 2013, 31(17), 2167-2172.
[http://dx.doi.org/10.1200/JCO.2012.47.7737] [PMID: 23630207]

Yang, J.D.; Hainaut, P.; Gores, G.J.; Amadou, A.; Plymoth, A.; Roberts, L.R. A global view of hepatocellular carcinoma: Trends, risk, prevention and management. Nat. Rev. Gastroenterol. Hepatol., 2019, 16(10), 589-604.
[http://dx.doi.org/10.1038/s41575-019-0186-y] [PMID: 31439937]

Llovet, J.M.; Zucman-Rossi, J.; Pikarsky, E.; Sangro, B.; Schwartz, M.; Sherman, M.; Gores, G. Hepatocellular carcinoma. Nat. Rev. Dis. Primers, 2016, 2(1), 16018.
[http://dx.doi.org/10.1038/nrdp.2016.18] [PMID: 27158749]

Guo, W.; Yang, X.R.; Sun, Y.F.; Shen, M.N.; Ma, X.L.; Wu, J.; Zhang, C.Y.; Zhou, Y.; Xu, Y.; Hu, B.; Zhang, X.; Zhou, J.; Fan, J. Clinical significance of EpCAM mRNA-positive circulating tumor cells in hepatocellular carcinoma by an optimized negative enrichment and qRT-PCR-based platform. Clin. Cancer Res., 2014, 20(18), 4794-4805.
[http://dx.doi.org/10.1158/1078-0432.CCR-14-0251] [PMID: 25009297]

de Boer, C.J.; van Krieken, J.H.J.M.; Janssen-van Rhijn, C.M.; Litvinov, S.V. Expression of Ep-CAM in normal, regenerating, metaplastic, and neoplastic liver. J. Pathol., 1999, 188(2), 201-206.
[http://dx.doi.org/10.1002/(SICI)1096-9896(199906)188:2<201::AID-PATH339>3.0.CO;2-8] [PMID: 10398165]

Kalinich, M.; Bhan, I.; Kwan, T.T.; Miyamoto, D.T.; Javaid, S. LiCausi, J.A.; Milner, J.D.; Hong, X.; Goyal, L.; Sil, S.; Choz, M.; Ho, U.; Kapur, R.; Muzikansky, A.; Zhang, H.; Weitz, D.A.; Sequist, L.V.; Ryan, D.P.; Chung, R.T.; Zhu, A.X.; Isselbacher, K.J.; Ting, D.T.; Toner, M.; Maheswaran, S.; Haber, D.A. An RNA-based signature enables high specificity detection of circulating tumor cells in hepatocellular carcinoma. Proc. Natl. Acad. Sci., 2017, 114(5), 1123-1128.
[http://dx.doi.org/10.1073/pnas.1617032114] [PMID: 28096363]

Court, C.M.; Hou, S.; Winograd, P.; Segel, N.H.; Li, Q.W.; Zhu, Y.; Sadeghi, S.; Finn, R.S.; Ganapathy, E.; Song, M.; French, S.W.; Naini, B.V.; Sho, S.; Kaldas, F.M.; Busuttil, R.W.; Tomlinson, J.S.; Tseng, H.R.; Agopian, V.G. A novel multimarker assay for the phenotypic profiling of circulating tumor cells in hepatocellular carcinoma. Liver Transpl., 2018, 24(7), 946-960.
[http://dx.doi.org/10.1002/lt.25062] [PMID: 29624843]

Guo, W.; Sun, Y.F.; Shen, M.N.; Ma, X.L.; Wu, J.; Zhang, C.Y.; Zhou, Y.; Xu, Y.; Hu, B.; Zhang, M.; Wang, G.; Chen, W.Q.; Guo, L.; Lu, R.Q.; Zhou, C.H.; Zhang, X.; Shi, Y.H.; Qiu, S.; Pan, B.; Cao, Y.; Zhou, J.; Yang, X.R.; Fan, J. Circulating tumor cells with stem-like phenotypes for diagnosis, prognosis, and therapeutic response evaluation in hepatocellular carcinoma. Clin. Cancer Res., 2018, 24(9), 2203-2213.
[http://dx.doi.org/10.1158/1078-0432.CCR-17-1753] [PMID: 29374055]

Cheng, Y.; Luo, L.; Zhang, J.; Zhou, M.; Tang, Y.; He, G.; Lu, Y.; Wang, Z.; Pan, M. Diagnostic value of different phenotype circulating tumor cells in hepatocellular carcinoma. J. Gastrointest. Surg., 2019, 23(12), 2354-2361.
[http://dx.doi.org/10.1007/s11605-018-04067-y] [PMID: 30805878]

Winograd, P.; Hou, S.; Court, C.M.; Lee, Y.T.; Chen, P.J.; Zhu, Y.; Sadeghi, S.; Finn, R.S.; Teng, P.C.; Wang, J.J.; Zhang, Z.; Liu, H.; Busuttil, R.W.; Tomlinson, J.S.; Tseng, H.R.; Agopian, V.G. Hepatocellular carcinoma–circulating tumor cells expressing PD‐L1 are prognostic and potentially associated with response to checkpoint inhibitors. Hepatol. Commun., 2020, 4(10), 1527-1540.
[http://dx.doi.org/10.1002/hep4.1577] [PMID: 33024921]

Hamaoka, M.; Kobayashi, T.; Tanaka, Y.; Mashima, H.; Ohdan, H. Clinical significance of glypican-3-positive circulating tumor cells of hepatocellular carcinoma patients: A prospective study. PLoS One, 2019, 14(5), e0217586.
[http://dx.doi.org/10.1371/journal.pone.0217586] [PMID: 31141571]

Zhang, J.; Zhang, M.; Ma, H.; Song, X.; He, L.; Ye, X.; Li, X. Overexpression of glypican-3 is a predictor of poor prognosis in hepatocellular carcinoma. Medicine, 2018, 97(24), e11130.
[http://dx.doi.org/10.1097/MD.0000000000011130] [PMID: 29901640]

Xu, F.; Jin, T.; Zhu, Y.; Dai, C. Immune checkpoint therapy in liver cancer. J. Exp. Clin. Cancer Res., 2018, 37(1), 110.
[http://dx.doi.org/10.1186/s13046-018-0777-4] [PMID: 29843754]

Saviano, A.; Henderson, N.C.; Baumert, T.F. Single-cell genomics and spatial transcriptomics: Discovery of novel cell states and cellular interactions in liver physiology and disease biology. J. Hepatol., 2020, 73(5), 1219-1230.
[http://dx.doi.org/10.1016/j.jhep.2020.06.004] [PMID: 32534107]

Kim, S.K.; Kim, Y.H.; Park, S.; Cho, S.W. Organoid engineering with microfluidics and biomaterials for liver, lung disease, and cancer modeling. Acta Biomater., 2021, 132, 37-51.
[http://dx.doi.org/10.1016/j.actbio.2021.03.002] [PMID: 33711526]

Lu, T.X.; Rothenberg, M.E. MicroRNA. J. Allergy Clin. Immunol., 2018, 141(4), 1202-1207.
[http://dx.doi.org/10.1016/j.jaci.2017.08.034] [PMID: 29074454]

Rupaimoole, R.; Slack, F.J. MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases. Nat. Rev. Drug Discov., 2017, 16(3), 203-222.
[http://dx.doi.org/10.1038/nrd.2016.246] [PMID: 28209991]

Kung, J.T.Y.; Colognori, D.; Lee, J.T. Long noncoding RNAs: Past, present, and future. Genetics, 2013, 193(3), 651-669.
[http://dx.doi.org/10.1534/genetics.112.146704] [PMID: 23463798]

Yoon, J.H.; Abdelmohsen, K.; Gorospe, M. Posttranscriptional gene regulation by long noncoding RNA. J. Mol. Biol., 2013, 425(19), 3723-3730.
[http://dx.doi.org/10.1016/j.jmb.2012.11.024] [PMID: 23178169]

Bhan, A.; Soleimani, M.; Mandal, S.S. Long noncoding RNA and cancer: A new paradigm. Cancer Res., 2017, 77(15), 3965-3981.
[http://dx.doi.org/10.1158/0008-5472.CAN-16-2634] [PMID: 28701486]

Li, X.; Yang, L.; Chen, L.L. The biogenesis, functions, and challenges of circular RNAs. Mol. Cell, 2018, 71(3), 428-442.
[http://dx.doi.org/10.1016/j.molcel.2018.06.034] [PMID: 30057200]

Wang, D.; Li, Z.; Wu, Y. The research progression and clinical significance of circular RNAs in head and neck cancers. BioMed Res. Int., 2020, 2020, 1-10.
[http://dx.doi.org/10.1155/2020/2712310] [PMID: 33150169]

Wu, W.; Zhen, T.; Yu, J.; Yang, Q. Circular RNAs as new regulators in gastric cancer: Diagnosis and cancer therapy. Front. Oncol., 2020, 10, 1526.
[http://dx.doi.org/10.3389/fonc.2020.01526] [PMID: 33072546]

Pigati, L.; Yaddanapudi, S.C.S.; Iyengar, R.; Kim, D.J.; Hearn, S.A.; Danforth, D.; Hastings, M.L.; Duelli, D.M. Selective release of microRNA species from normal and malignant mammary epithelial cells. PLoS One, 2010, 5(10), e13515.
[http://dx.doi.org/10.1371/journal.pone.0013515] [PMID: 20976003]

Tomimaru, Y.; Eguchi, H.; Nagano, H.; Wada, H.; Kobayashi, S.; Marubashi, S.; Tanemura, M.; Tomokuni, A.; Takemasa, I.; Umeshita, K.; Kanto, T.; Doki, Y.; Mori, M. Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma. J. Hepatol., 2012, 56(1), 167-175.
[http://dx.doi.org/10.1016/j.jhep.2011.04.026] [PMID: 21749846]

Shaker, O.G.; Abdelwahed, M.Y.; Ahmed, N.A.; Hassan, E.A.; Ahmed, T.I.; Abousarie, M.A.; Ayoub, S.E. Evaluation of serum long noncoding RNA NEAT and MiR‐129‐5p in hepatocellular carcinoma. IUBMB Life, 2019, 71(10), 1571-1578.
[http://dx.doi.org/10.1002/iub.2096] [PMID: 31190421]

Jin, Y.; Wong, Y.S.; Goh, B.K.P.; Chan, C.Y.; Cheow, P.C.; Chow, P.K.H.; Lim, T.K.H.; Goh, G.B.B.; Krishnamoorthy, T.L.; Kumar, R.; Ng, T.P.; Chong, S.S.; Tan, H.H.; Chung, A.Y.F.; Ooi, L.L.P.J.; Chang, J.P.E.; Tan, C.K.; Lee, C.G.L. Circulating microRNAs as potential diagnostic and prognostic biomarkers in hepatocellular carcinoma. Sci. Rep., 2019, 9(1), 10464.
[http://dx.doi.org/10.1038/s41598-019-46872-8] [PMID: 31320713]

Ali, H.S.; Boshra, M.S.; El Meteini, M.S.; Shafei, A.E.S.; Matboli, M. lncRNA- RP11-156p1.3, novel diagnostic and therapeutic targeting via CRISPR/Cas9 editing in hepatocellular carcinoma. Genomics, 2020, 112(5), 3306-3314.
[http://dx.doi.org/10.1016/j.ygeno.2020.06.020] [PMID: 32544548]

Han, J.; Li, J.; Qian, Y.; Liu, W.; Liang, J.; Huang, Z.; Wang, S.; Zhao, C. Identification of plasma miR-148a as a noninvasive biomarker for hepatocellular carcinoma. Clin. Res. Hepatol. Gastroenterol., 2019, 43(5), 585-593.
[http://dx.doi.org/10.1016/j.clinre.2018.12.008] [PMID: 30824368]

Cao, C.; Wang, C. Clinical significance of serum miR-768-3p in HBV-related hepatocellular carcinoma and its potential mechanism. Clin. Exp. Med., 2020, 20(4), 569-576.
[http://dx.doi.org/10.1007/s10238-020-00646-z] [PMID: 32712720]

Zeng, Z.; Dong, J.; Li, Y.; Dong, Z.; Liu, Z.; Huang, J.; Wang, Y.; Zhen, Y.; Lu, Y. The expression level and diagnostic value of microRNA-22 in HCC patients. Artif. Cells Nanomed. Biotechnol., 2020, 48(1), 683-686.
[http://dx.doi.org/10.1080/21691401.2019.1703723] [PMID: 32088997]

Wu, J.; Wu, Y.; Luo, Y.; Li, X.; Lin, N.; Yang, X.; Lin, Y.; Chen, M. Circulating miRNA-199a and miRNA-122 levels as potential diagnostic and prognostic biomarkers for hepatocellular carcinoma. Ann. Clin. Lab. Sci., 2020, 50(2), 219-227.
[PMID: 32366560]

Zhou, G.; Zeng, Y.; Luo, Y.; Guo, S.; Bao, L.; Zhang, Q. Urine miR-93-5p is a promising biomarker for early detection of HBV-related hepatocellular carcinoma. Eur. J. Surg. Oncol., 2022, 48(1), 95-102.
[http://dx.doi.org/10.1016/j.ejso.2021.06.015] [PMID: 34175168]

Zeng, Z.; Dong, J.; Li, Y.; Dong, Z.; Liu, Z.; Huang, J.; Wang, Y.; Zhen, Y.; Yinying, Lu, The expression level and clinical significance of lncRNA X91348 in hepatocellular carcinoma. Artif. Cells Nanomed. Biotechnol., 2019, 47(1), 3067-3071.
[http://dx.doi.org/10.1080/21691401.2019.1640228] [PMID: 31349749]

Hu, W.; Feng, H.; Xu, X.; Huang, X.; Huang, X.; Chen, W.; Hao, L.; Xia, W. Long noncoding RNA FOXD2‐AS1 aggravates hepatocellular carcinoma tumorigenesis by regulating the miR‐206/MAP3K1 axis. Cancer Med., 2020, 9(15), 5620-5631.
[http://dx.doi.org/10.1002/cam4.3204] [PMID: 32558350]

Huang, J.; Zheng, Y.; Xiao, X.; Liu, C.; Lin, J.; Zheng, S.; Yang, B.; Ou, Q. A circulating long noncoding RNA panel serves as a diagnostic marker for hepatocellular carcinoma. Dis. Markers, 2020, 2020, 1-12.
[http://dx.doi.org/10.1155/2020/5417598] [PMID: 32733618]

Han, Y.; Jiang, W.; Wang, Y.; Zhao, M.; Li, Y.; Ren, L. Serum long non-coding RNA SCARNA10 serves as a potential diagnostic biomarker for hepatocellular carcinoma. BMC Cancer, 2022, 22(1), 431.
[http://dx.doi.org/10.1186/s12885-022-09530-3] [PMID: 35443674]

Zeng, Y.L.; Guo, Z.Y.; Su, H.Z.; Zhong, F.D.; Jiang, K.Q.; Yuan, G.D. Diagnostic and prognostic value of lncRNA cancer susceptibility candidate 9 in hepatocellular carcinoma. World J. Gastroenterol., 2019, 25(48), 6902-6915.
[http://dx.doi.org/10.3748/wjg.v25.i48.6902] [PMID: 31908394]

Zhang, X.; Xu, Y.; Qian, Z.; Zheng, W.; Wu, Q.; Chen, Y.; Zhu, G.; Liu, Y.; Bian, Z.; Xu, W.; Zhang, Y.; Sun, F.; Pan, Q.; Wang, J.; Du, L.; Yu, Y. circRNA_104075 stimulates YAP-dependent tumorigenesis through the regulation of HNF4a and may serve as a diagnostic marker in hepatocellular carcinoma. Cell Death Dis., 2018, 9(11), 1091.
[http://dx.doi.org/10.1038/s41419-018-1132-6] [PMID: 30361504]

Zhang, X.; Zhou, H.; Jing, W.; Luo, P.; Qiu, S.; Liu, X.; Zhu, M.; Liang, C.; Yu, M.; Tu, J. The Circular RNA hsa_circ_0001445 regulates the proliferation and migration of hepatocellular carcinoma and may serve as a diagnostic biomarker. Dis. Markers, 2018, 2018, 1-9.
[http://dx.doi.org/10.1155/2018/3073467] [PMID: 29785229]

Matboli, M.; Shafei, A.E.; Ali, M.A.; Ashry, A.M.; Kamal, K.M.; Agag, M.A. circRNAs (hsa_circ_00156, hsa_circ _000224, and hsa_circ _000520) are novel potential biomarkers in hepatocellular carcinoma. J. Cell. Biochem., 2019, 120(5), 7711-7724.
[PMID: 30426540]

Li, Z.; Zhou, Y.; Yang, G.; He, S.; Qiu, X.; Zhang, L.; Deng, Q.; Zheng, F. Using circular RNA SMARCA5 as a potential novel biomarker for hepatocellular carcinoma. Clin. Chim. Acta, 2019, 492, 37-44.
[http://dx.doi.org/10.1016/j.cca.2019.02.001] [PMID: 30716279]

Wang, W.; Li, Y.; Li, X.; Liu, B.; Han, S.; Li, X.; Zhang, B.; Li, J.; Sun, S. Circular RNA circ-FOXP1 induced by SOX9 promotes hepatocellular carcinoma progression via sponging miR-875-3p and miR-421. Biomed. Pharmacother., 2020, 121, 109517.
[http://dx.doi.org/10.1016/j.biopha.2019.109517] [PMID: 31698267]

Zhu, K.; Zhan, H.; Peng, Y.; Yang, L.; Gao, Q.; Jia, H.; Dai, Z.; Tang, Z.; Fan, J.; Zhou, J. Plasma hsa_circ_0027089 is a diagnostic biomarker for hepatitis B virus-related hepatocellular carcinoma. Carcinogenesis, 2020, 41(3), 296-302.
[http://dx.doi.org/10.1093/carcin/bgz154] [PMID: 31535687]

Liu, R.; Li, Y.; Wu, A.; Kong, M.; Ding, W.; Hu, Z.; Chen, L.; Cai, W.; Wang, F. Identification of plasma hsa_circ_0005397 and combined with serum AFP, AFP-L3 as potential biomarkers for hepatocellular carcinoma. Front. Pharmacol., 2021, 12, 639963.
[http://dx.doi.org/10.3389/fphar.2021.639963] [PMID: 33679420]

Song, Y.; Cao, P.; Li, J. Plasma circular RNA hsa_circ_0001821 acts as a novel diagnostic biomarker for malignant tumors. J. Clin. Lab. Anal., 2021, 35(11), e24009.
[http://dx.doi.org/10.1002/jcla.24009] [PMID: 34523755]

Zhou, J.; Yu, L.; Gao, X.; Hu, J.; Wang, J.; Dai, Z.; Wang, J.F.; Zhang, Z.; Lu, S.; Huang, X.; Wang, Z.; Qiu, S.; Wang, X.; Yang, G.; Sun, H.; Tang, Z.; Wu, Y.; Zhu, H.; Fan, J. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J. Clin. Oncol., 2011, 29(36), 4781-4788.
[http://dx.doi.org/10.1200/JCO.2011.38.2697] [PMID: 22105822]

Zhang, N.; Hu, Z.; Qiang, Y.; Zhu, X. Circulating miR‐130b‐ and miR‐21‐based diagnostic markers and therapeutic targets for hepatocellular carcinoma. Mol. Genet. Genomic Med., 2019, 7(12), e1012.
[http://dx.doi.org/10.1002/mgg3.1012] [PMID: 31660696]

Lin, X.J.; Chong, Y.; Guo, Z.W.; Xie, C.; Yang, X.J.; Zhang, Q.; Li, S.P.; Xiong, Y.; Yuan, Y.; Min, J.; Jia, W.H.; Jie, Y.; Chen, M.S.; Chen, M.X.; Fang, J.H.; Zeng, C.; Zhang, Y.; Guo, R.P.; Wu, Y.; Lin, G.; Zheng, L.; Zhuang, S.M. A serum microRNA classifier for early detection of hepatocellular carcinoma: A multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study. Lancet Oncol., 2015, 16(7), 804-815.
[http://dx.doi.org/10.1016/S1470-2045(15)00048-0] [PMID: 26088272]

Zhu, H.T.; Liu, R.B.; Liang, Y.Y.; Hasan, A.M.E.; Wang, H.Y.; Shao, Q.; Zhang, Z.C.; Wang, J.; He, C.Y.; Wang, F.; Shao, J.Y. Serum microRNA profiles as diagnostic biomarkers for HBV-positive hepatocellular carcinoma. Liver Int., 2017, 37(6), 888-896.
[http://dx.doi.org/10.1111/liv.13356] [PMID: 28061012]

An, Y.; Gao, S.; Zhao, W.C.; Qiu, B.A.; Xia, N.X.; Zhang, P.J.; Fan, Z.P. Novel serum microRNAs panel on the diagnostic and prognostic implications of hepatocellular carcinoma. World J. Gastroenterol., 2018, 24(24), 2596-2604.
[http://dx.doi.org/10.3748/wjg.v24.i24.2596] [PMID: 29962816]

Chen, S.; Fu, Z.; Wen, S.; Yang, X.; Yu, C.; Zhou, W.; Lin, Y.; Lv, Y. Expression and diagnostic value of miR-497 and miR-1246 in hepatocellular carcinoma. Front. Genet., 2021, 12, 666306.
[http://dx.doi.org/10.3389/fgene.2021.666306] [PMID: 34163524]

Yamamoto, Y.; Kondo, S.; Matsuzaki, J.; Esaki, M.; Okusaka, T.; Shimada, K.; Murakami, Y.; Enomoto, M.; Tamori, A.; Kato, K.; Aoki, Y.; Takizawa, S.; Sakamoto, H.; Niida, S.; Takeshita, F.; Ochiya, T. Highly sensitive circulating MicroRNA panel for accurate detection of hepatocellular carcinoma in patients with liver disease. Hepatol. Commun., 2020, 4(2), 284-297.
[http://dx.doi.org/10.1002/hep4.1451] [PMID: 32025611]

Yao, J.; Hua, X.; Shi, J.; Hu, X.; Lui, K.; He, K.; Mai, J.; Lan, T.; Lu, M. LncRNA THEMIS2‐211, a tumor‐originated circulating exosomal biomarker, promotes the growth and metastasis of hepatocellular carcinoma by functioning as a competing endogenous RNA. FASEB J., 2022, 36(4), e22238.
[http://dx.doi.org/10.1096/fj.202101564R] [PMID: 35224785]

Wu, C.; Deng, L.; Zhuo, H.; Chen, X.; Tan, Z.; Han, S.; Tang, J.; Qian, X.; Yao, A. Circulating circRNA predicting the occurrence of hepatocellular carcinoma in patients with HBV infection. J. Cell. Mol. Med., 2020, 24(17), 10216-10222.
[http://dx.doi.org/10.1111/jcmm.15635] [PMID: 32692470]

Sun, X.H.; Wang, Y.T.; Li, G.F.; Zhang, N.; Fan, L. Serum-derived three-circRNA signature as a diagnostic biomarker for hepatocellular carcinoma. Cancer Cell Int., 2020, 20(1), 226.
[http://dx.doi.org/10.1186/s12935-020-01302-y] [PMID: 32536814]

Yu, J.; Ding, W.; Wang, M.; Guo, X.; Xu, J.; Xu, Q.; Yang, Y.; Sun, S.; Liu, J.; Qin, L.; Liu, H.; Yang, F.; Zhou, W. Plasma circular RNA panel to diagnose hepatitis B virus‐related hepatocellular carcinoma: A large‐scale, multicenter study. Int. J. Cancer, 2020, 146(6), 1754-1763.
[http://dx.doi.org/10.1002/ijc.32647] [PMID: 31456215]

Habieb, A.; Matboli, M.; El-Tayeb, H.; El-Asmar, F. Potential role of lncRNA-TSIX, miR-548-a-3p, and SOGA1 mRNA in the diagnosis of hepatocellular carcinoma. Mol. Biol. Rep., 2019, 46(4), 4581-4590.
[http://dx.doi.org/10.1007/s11033-019-04810-x] [PMID: 31004302]

Fouda, M.S.; Omran, M.M.; Tarek, G.; Hady, A.; Abdel Wahab, A.; Abdel Wahab, A. Development of a novel panel based on micro-RNAs (21, 29a, 200 and 335) and alpha-fetoprotein as diagnostic biomarkers for hepatocellular carcinoma associated with hepatitis C infection. Arab J. Gastroenterol., 2021, 22(1), 28-33.
[http://dx.doi.org/10.1016/j.ajg.2020.08.004] [PMID: 33268243]

Gharib, A.F.; Eed, E.M.; Khalifa, A.S.; Raafat, N.; Shehab-Eldeen, S.; Alwakeel, H.R.; Darwiesh, E.; Essa, A. Value of Serum miRNA-96-5p and miRNA-99a-5p as diagnostic biomarkers for hepatocellular carcinoma. Int. J. Gen. Med., 2022, 15, 2427-2436.
[http://dx.doi.org/10.2147/IJGM.S354842] [PMID: 35264879]

Kamel, M.M.; Matboli, M.; Sallam, M.; Montasser, I.F.; Saad, A.S.; El-Tawdi, A.H.F. Investigation of long noncoding RNAs expression profile as potential serum biomarkers in patients with hepatocellular carcinoma. Transl. Res., 2016, 168, 134-145.
[http://dx.doi.org/10.1016/j.trsl.2015.10.002] [PMID: 26551349]

Tian, Z.; Yu, T.; Wei, H.; Ning, N. Clinical value of LHPP‐associated microRNAs combined with protein induced by vitamin K deficiency or antagonist‐II in the diagnosis of alpha‐fetoprotein‐negative hepatocellular carcinoma. J. Clin. Lab. Anal., 2020, 34(2), e23071.
[http://dx.doi.org/10.1002/jcla.23071] [PMID: 31693242]

Ming, X.L.; Feng, Y.L.; He, D.D.; Luo, C.L.; Rong, J.L.; Zhang, W.W.; Ye, P.; Chai, H.Y.; Liang, C.Z.; Tu, J.C. Role of BCYRN1 in hepatocellular carcinoma pathogenesis by lncRNA–miRNA–mRNA network analysis and its diagnostic and prognostic value. Epigenomics, 2019, 11(10), 1209-1231.
[http://dx.doi.org/10.2217/epi-2018-0218] [PMID: 31339046]

Kalluri, R.; LeBleu, V.S. The biology, function, and biomedical applications of exosomes. Science, 2020, 367(6478), eaau6977.
[http://dx.doi.org/10.1126/science.aau6977] [PMID: 32029601]

Hu, S.; Li, Z.; Shen, D.; Zhu, D.; Huang, K.; Su, T.; Dinh, P.U.; Cores, J.; Cheng, K. Exosome-eluting stents for vascular healing after ischaemic injury. Nat. Biomed. Eng., 2021, 5(10), 1174-1188.
[http://dx.doi.org/10.1038/s41551-021-00705-0] [PMID: 33820981]

Zhu, Y.; Wang, S.; Xi, X.; Zhang, M.; Liu, X.; Tang, W.; Cai, P.; Xing, S.; Bao, P.; Jin, Y.; Zhao, W.; Chen, Y.; Zhao, H.; Jia, X.; Lu, S.; Lu, Y.; Chen, L.; Yin, J.; Lu, Z.J. Integrative analysis of long extracellular RNAs reveals a detection panel of noncoding RNAs for liver cancer. Theranostics, 2021, 11(1), 181-193.
[http://dx.doi.org/10.7150/thno.48206] [PMID: 33391469]

Wang, Y.; Zhang, C.; Zhang, P.; Guo, G.; Jiang, T.; Zhao, X.; Jiang, J.; Huang, X.; Tong, H.; Tian, Y. Serum exosomal microRNAs combined with alpha-fetoprotein as diagnostic markers of hepatocellular carcinoma. Cancer Med., 2018, 7(5), 1670-1679.
[http://dx.doi.org/10.1002/cam4.1390] [PMID: 29573235]

Huang, X.; Sun, L.; Wen, S.; Deng, D.; Wan, F.; He, X.; Tian, L.; Liang, L.; Wei, C.; Gao, K.; Fu, Q.; Li, Y.; Jiang, J.; Zhai, R.; He, M. RNA sequencing of plasma exosomes revealed novel functional long noncoding RNAs in hepatocellular carcinoma. Cancer Sci., 2020, 111(9), 3338-3349.
[http://dx.doi.org/10.1111/cas.14516] [PMID: 32506598]

Lu, Y.; Duan, Y.; Xu, Q.; Zhang, L.; Chen, W.; Qu, Z.; Wu, B.; Liu, W.; Shi, L.; Wu, D.; Yang, Y.; Sun, D.; Chen, X. Circulating exosome‐derived bona fide long non‐coding RNAs predicting the occurrence and metastasis of hepatocellular carcinoma. J. Cell. Mol. Med., 2020, 24(2), 1311-1318.
[http://dx.doi.org/10.1111/jcmm.14783] [PMID: 31811749]

Xu, H.; Dong, X.; Chen, Y.; Wang, X. Serum exosomal hnRNPH1 mRNA as a novel marker for hepatocellular carcinoma. Clin. Chem. Lab. Med., 2018, 56(3), 479-484.
[http://dx.doi.org/10.1515/cclm-2017-0327] [PMID: 29252188]

Cho, H.; Eun, J.; Baek, G.; Seo, C.; Ahn, H.; Kim, S.; Cho, S.; Cheong, J. Serum Exosomal MicroRNA, miR-10b-5p, as a potential diagnostic biomarker for early-stage hepatocellular carcinoma. J. Clin. Med., 2020, 9(1), 281.
[http://dx.doi.org/10.3390/jcm9010281] [PMID: 31968558]

Hao, X.; Xin, R.; Dong, W. Decreased serum exosomal miR-320a expression is an unfavorable prognostic factor in patients with hepatocellular carcinoma. J. Int. Med. Res., 2020, 48(4), 0300060519896144.
[http://dx.doi.org/10.1177/0300060519896144] [PMID: 32339037]

Sun, N.; Lee, Y.T.; Zhang, R.Y.; Kao, R.; Teng, P.C.; Yang, Y.; Yang, P.; Wang, J.J.; Smalley, M.; Chen, P.J.; Kim, M.; Chou, S.J.; Bao, L.; Wang, J.; Zhang, X.; Qi, D.; Palomique, J.; Nissen, N.; Han, S.H.B.; Sadeghi, S.; Finn, R.S.; Saab, S.; Busuttil, R.W.; Markovic, D.; Elashoff, D.; Yu, H.; Li, H.; Heaney, A.P.; Posadas, E.; You, S.; Yang, J.D.; Pei, R.; Agopian, V.G.; Tseng, H.R.; Zhu, Y. Purification of HCC-specific extracellular vesicles on nanosubstrates for early HCC detection by digital scoring. Nat. Commun., 2020, 11(1), 4489.
[http://dx.doi.org/10.1038/s41467-020-18311-0] [PMID: 32895384]

Tan, C.; Cao, J.; Chen, L.; Xi, X.; Wang, S.; Zhu, Y.; Yang, L.; Ma, L.; Wang, D.; Yin, J.; Zhang, T.; John Lu, Z. Noncoding RNAs serve as diagnosis and prognosis biomarkers for hepatocellular carcinoma. Clin. Chem., 2019, 65(7), 905-915.
[http://dx.doi.org/10.1373/clinchem.2018.301150] [PMID: 30996051]

Cui, Z.; Li, Y.; Gao, Y.; Kong, L.; Lin, Y.; Chen, Y. Cancer-testis antigen lactate dehydrogenase C4 in hepatocellular carcinoma: A promising biomarker for early diagnosis, efficacy evaluation and prognosis prediction. Aging (Albany NY), 2020, 12(19), 19455-19467.
[http://dx.doi.org/10.18632/aging.103879] [PMID: 33035196]

Wang, X.; Kwak, K.J.; Yang, Z.; Zhang, A.; Zhang, X.; Sullivan, R.; Lin, D.; Lee, R.L.; Castro, C.; Ghoshal, K.; Schmidt, C.; Lee, L.J. Extracellular mRNA detected by molecular beacons in tethered lipoplex nanoparticles for diagnosis of human hepatocellular carcinoma. PLoS One, 2018, 13(6), e0198552.
[http://dx.doi.org/10.1371/journal.pone.0198552] [PMID: 29879168]

Sorop, A.; Iacob, R.; Iacob, S.; Constantinescu, D.; Chitoiu, L.; Fertig, T.E.; Dinischiotu, A.; Chivu-Economescu, M.; Bacalbasa, N.; Savu, L.; Gheorghe, L.; Dima, S.; Popescu, I. Plasma small extracellular vesicles derived miR-21-5p and miR-92a-3p as potential biomarkers for hepatocellular carcinoma screening. Front. Genet., 2020, 11, 712.
[http://dx.doi.org/10.3389/fgene.2020.00712] [PMID: 32793278]

Arbelaiz, A.; Azkargorta, M.; Krawczyk, M.; Santos-Laso, A.; Lapitz, A.; Perugorria, M.J.; Erice, O.; Gonzalez, E.; Jimenez-Agüero, R.; Lacasta, A.; Ibarra, C.; Sanchez-Campos, A.; Jimeno, J.P.; Lammert, F.; Milkiewicz, P.; Marzioni, M.; Macias, R.I.R.; Marin, J.J.G.; Patel, T.; Gores, G.J.; Martinez, I.; Elortza, F.; Falcon-Perez, J.M.; Bujanda, L.; Banales, J.M. Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma. Hepatology, 2017, 66(4), 1125-1143.
[http://dx.doi.org/10.1002/hep.29291] [PMID: 28555885]

Julich-Haertel, H.; Urban, S.K.; Krawczyk, M.; Willms, A.; Jankowski, K.; Patkowski, W.; Kruk, B.; Krasnodębski, M.; Ligocka, J.; Schwab, R.; Richardsen, I.; Schaaf, S.; Klein, A.; Gehlert, S.; Sänger, H.; Casper, M.; Banales, J.M.; Schuppan, D.; Milkiewicz, P.; Lammert, F.; Krawczyk, M.; Lukacs-Kornek, V.; Kornek, M. Cancer-associated circulating large extracellular vesicles in cholangiocarcinoma and hepatocellular carcinoma. J. Hepatol., 2017, 67(2), 282-292.
[http://dx.doi.org/10.1016/j.jhep.2017.02.024] [PMID: 28267620]

Sohn, W.; Kim, J.; Kang, S.H.; Yang, S.R.; Cho, J.Y.; Cho, H.C.; Shim, S.G.; Paik, Y.H. Serum exosomal microRNAs as novel biomarkers for hepatocellular carcinoma. Exp. Mol. Med., 2015, 47(9), e184.
[http://dx.doi.org/10.1038/emm.2015.68] [PMID: 26380927]

Cho, H.J.; Baek, G.O.; Seo, C.W.; Ahn, H.R.; Sung, S.; Son, J.A.; Kim, S.S.; Cho, S.W.; Jang, J.W.; Nam, S.W.; Cheong, J.Y.; Eun, J.W. Exosomal microRNA‐4661‐5p–based serum panel as a potential diagnostic biomarker for early‐stage hepatocellular carcinoma. Cancer Med., 2020, 9(15), 5459-5472.
[http://dx.doi.org/10.1002/cam4.3230] [PMID: 32537885]

Ghosh, S.; Bhowmik, S.; Majumdar, S.; Goswami, A.; Chakraborty, J.; Gupta, S.; Aggarwal, S.; Ray, S.; Chatterjee, R.; Bhattacharyya, S.; Dutta, M.; Datta, S.; Chowdhury, A.; Dhali, G.K.; Banerjee, S. The exosome encapsulated Micrornas as circulating diagnostic marker for hepatocellular carcinoma with low alpha‐fetoprotein. Int. J. Cancer, 2020, 147(10), 2934-2947.
[http://dx.doi.org/10.1002/ijc.33111] [PMID: 32441313]

Pu, C.; Huang, H.; Wang, Z.; Zou, W.; Lv, Y.; Zhou, Z.; Zhang, Q.; Qiao, L.; Wu, F.; Shao, S. Extracellular vesicle-associated mir-21 and mir-144 are markedly elevated in serum of patients with hepatocellular carcinoma. Front. Physiol., 2018, 9, 930.
[http://dx.doi.org/10.3389/fphys.2018.00930] [PMID: 30065664]

Zhang, Y.; Xi, H.; Nie, X.; Zhang, P.; Lan, N.; Lu, Y.; Liu, J.; Yuan, W. Assessment of miR-212 and other biomarkers in the diagnosis and treatment of HBV-infection-related liver diseases. Curr. Drug Metab., 2019, 20(10), 785-798.
[http://dx.doi.org/10.2174/1389200220666191011120434] [PMID: 31608838]

Wang, T.; Zhu, H.; Xiao, M.; Zhou, S. Serum exosomal long noncoding RNA CRNDE as a prognostic biomarker for hepatocellular carcinoma. J. Clin. Lab. Anal., 2021, 35(11), e23959.
[http://dx.doi.org/10.1002/jcla.23959] [PMID: 34612554]

Kim, S.S.; Baek, G.O.; Ahn, H.R.; Sung, S.; Seo, C.W.; Cho, H.J.; Nam, S.W.; Cheong, J.Y.; Eun, J.W. Serum small extracellular vesicle‐derived LINC00853 as a novel diagnostic marker for early hepatocellular carcinoma. Mol. Oncol., 2020, 14(10), 2646-2659.
[http://dx.doi.org/10.1002/1878-0261.12745] [PMID: 32525601]

Xu, H.; Chen, Y.; Dong, X.; Wang, X. Serum Exosomal Long Noncoding RNAs ENSG00000258332.1 and LINC00635 for the diagnosis and prognosis of hepatocellular carcinoma. Cancer Epidemiol. Biomarkers Prev., 2018, 27(6), 710-716.
[http://dx.doi.org/10.1158/1055-9965.EPI-17-0770] [PMID: 29650788]

Abd El Gwad, A.; Matboli, M.; El-Tawdi, A.; Habib, E.K.; Shehata, H.; Ibrahim, D.; Tash, F. Role of exosomal competing endogenous RNA in patients with hepatocellular carcinoma. J. Cell. Biochem., 2018, 119(10), 8600-8610.
[http://dx.doi.org/10.1002/jcb.27109] [PMID: 30015383]

Best, M.G.; Sol, N.; Kooi, I.; Tannous, J.; Westerman, B.A.; Rustenburg, F.; Schellen, P.; Verschueren, H.; Post, E.; Koster, J.; Ylstra, B.; Ameziane, N.; Dorsman, J.; Smit, E.F.; Verheul, H.M.; Noske, D.P.; Reijneveld, J.C.; Nilsson, R.J.A.; Tannous, B.A.; Wesseling, P.; Wurdinger, T. RNA-Seq of tumor-educated platelets enables blood-based pan-cancer, multiclass, and molecular pathway cancer diagnostics. Cancer Cell, 2015, 28(5), 666-676.
[http://dx.doi.org/10.1016/j.ccell.2015.09.018] [PMID: 26525104]

Li, X.; Liu, L.; Song, X.; Wang, K.; Niu, L.; Xie, L.; Song, X. TEP linc-GTF2H2-1, RP3-466P17.2, and lnc-ST8SIA4-12 as novel biomarkers for lung cancer diagnosis and progression prediction. J. Cancer Res. Clin. Oncol., 2021, 147(6), 1609-1622.
[http://dx.doi.org/10.1007/s00432-020-03502-5] [PMID: 33792796]

Wang, B.; Zhu, J.; Ma, X.; Wang, H.; Qiu, S.; Pan, B.; Zhou, J.; Fan, J.; Yang, X.; Guo, W.; Cheng, Y. Platelet activation status in the diagnosis and postoperative prognosis of hepatocellular carcinoma. Clin. Chim. Acta, 2019, 495, 191-197.
[http://dx.doi.org/10.1016/j.cca.2019.03.1634] [PMID: 30946815]

Zhu, B.; Gu, S.; Wu, X.; He, W.; Zhou, H. Bioinformatics analysis of tumor-educated platelet microRNAs in patients with hepatocellular carcinoma. Biosci. Rep., 2021, 41(12), BSR20211420.
[http://dx.doi.org/10.1042/BSR20211420] [PMID: 34806748]

Asghar, S.; Waqar, W.; Umar, M.; Manzoor, S. Tumor educated platelets, a promising source for early detection of hepatocellular carcinoma: Liquid biopsy an alternative approach to tissue biopsy. Clin. Res. Hepatol. Gastroenterol., 2020, 44(6), 836-844.
[http://dx.doi.org/10.1016/j.clinre.2020.03.023] [PMID: 32312598]

Waqar, W.; Asghar, S.; Manzoor, S. Platelets’ RNA as biomarker trove for differentiation of early-stage hepatocellular carcinoma from underlying cirrhotic nodules. PLoS One, 2021, 16(9), e0256739.
[http://dx.doi.org/10.1371/journal.pone.0256739] [PMID: 34469466]

Masuzaki, R.; Karp, S.J.; Omata, M. New serum markers of hepatocellular carcinoma. Semin. Oncol., 2012, 39(4), 434-439.
[http://dx.doi.org/10.1053/j.seminoncol.2012.05.009] [PMID: 22846860]

Mahalingam, D.; Chelis, L.; Nizamuddin, I.; Lee, S.S.; Kakolyris, S.; Halff, G.; Washburn, K.; Attwood, K.; Fahad, I.; Grigorieva, J.; Asmellash, S.; Meyer, K.; Oliveira, C.; Roder, H.; Roder, J.; Iyer, R. Detection of hepatocellular carcinoma in a high-risk population by a mass spectrometry-based test. Cancers (Basel), 2021, 13(13), 3109.
[http://dx.doi.org/10.3390/cancers13133109] [PMID: 34206321]

Zhang, S.; Liu, Y.; Chen, J.; Shu, H.; Shen, S.; Li, Y.; Lu, X.; Cao, X.; Dong, L.; Shi, J.; Cao, Y.; Wang, X.; Zhou, J.; Liu, Y.; Chen, L.; Fan, J.; Ding, G.; Gao, Q. Autoantibody signature in hepatocellular carcinoma using seromics. J. Hematol. Oncol., 2020, 13(1), 85.
[http://dx.doi.org/10.1186/s13045-020-00918-x] [PMID: 32616055]

Han, J.; Han, M.; Xing, H.; Li, Z.; Yuan, D.; Wu, H.; Zhang, H.; Wang, M.; Li, C.; Liang, L.; Song, Y.; Xu, A.; Wu, M.; Shen, F.; Xie, Y.; Yang, T. Tissue and serum metabolomic phenotyping for diagnosis and prognosis of hepatocellular carcinoma. Int. J. Cancer, 2020, 146(6), 1741-1753.
[http://dx.doi.org/10.1002/ijc.32599] [PMID: 31361910]

Lu, Y.; Li, N.; Gao, L.; Xu, Y.J.; Huang, C.; Yu, K.; Ling, Q.; Cheng, Q.; Chen, S.; Zhu, M.; Fang, J.; Chen, M.; Ong, C.N. Acetylcarnitine is a candidate diagnostic and prognostic biomarker of hepatocellular carcinoma. Cancer Res., 2016, 76(10), 2912-2920.
[http://dx.doi.org/10.1158/0008-5472.CAN-15-3199] [PMID: 26976432]

Kim, D.; Cho, E.; Yu, K.S.; Jang, I.J.; Yoon, J.H.; Park, T.; Cho, J.Y. Comprehensive metabolomic search for biomarkers to differentiate early stage hepatocellular carcinoma from cirrhosis. Cancers, 2019, 11(10), 1497.
[http://dx.doi.org/10.3390/cancers11101497] [PMID: 31590436]

Zeng, J.; Yin, P.; Tan, Y.; Dong, L.; Hu, C.; Huang, Q.; Lu, X.; Wang, H.; Xu, G. Metabolomics study of hepatocellular carcinoma: discovery and validation of serum potential biomarkers by using capillary electrophoresis-mass spectrometry. J. Proteome Res., 2014, 13(7), 3420-3431.
[http://dx.doi.org/10.1021/pr500390y] [PMID: 24853826]

Ladep, N.G.; Dona, A.C.; Lewis, M.R.; Crossey, M.M.E.; Lemoine, M.; Okeke, E.; Shimakawa, Y.; Duguru, M.; Njai, H.F.; Fye, H.K.S.; Taal, M.; Chetwood, J.; Kasstan, B.; Khan, S.A.; Garside, D.A.; Wijeyesekera, A.; Thillainayagam, A.V.; Banwat, E.; Thursz, M.R.; Nicholson, J.K.; Njie, R.; Holmes, E.; Taylor-Robinson, S.D. Discovery and validation of urinary metabotypes for the diagnosis of hepatocellular carcinoma in West Africans. Hepatology, 2014, 60(4), 1291-1301.
[http://dx.doi.org/10.1002/hep.27264] [PMID: 24923488]

Banales, J.M.; Iñarrairaegui, M.; Arbelaiz, A.; Milkiewicz, P.; Muntané, J.; Muñoz-Bellvis, L.; La Casta, A.; Gonzalez, L.M.; Arretxe, E.; Alonso, C.; Martínez-Arranz, I.; Lapitz, A.; Santos-Laso, A.; Avila, M.A.; Martínez-Chantar, M.L.; Bujanda, L.; Marin, J.J.G.; Sangro, B.; Macias, R.I.R. Serum Metabolites as Diagnostic Biomarkers for Cholangiocarcinoma, Hepatocellular Carcinoma, and Primary Sclerosing Cholangitis. Hepatology, 2019, 70(2), 547-562.
[http://dx.doi.org/10.1002/hep.30319] [PMID: 30325540]

Nicholson, J.K.; Lindon, J.C.; Holmes, E. ‘Metabonomics’: understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica, 1999, 29(11), 1181-1189.
[http://dx.doi.org/10.1080/004982599238047] [PMID: 10598751]

Beyoğlu, D.; Idle, J.R. Metabolomic and lipidomic biomarkers for premalignant liver disease diagnosis and therapy. Metabolites, 2020, 10(2), 50.
[http://dx.doi.org/10.3390/metabo10020050] [PMID: 32012846]

Wishart, D.S.; Lewis, M.J.; Morrissey, J.A.; Flegel, M.D.; Jeroncic, K.; Xiong, Y.; Cheng, D.; Eisner, R.; Gautam, B.; Tzur, D.; Sawhney, S.; Bamforth, F.; Greiner, R.; Li, L. The human cerebrospinal fluid metabolome. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2008, 871(2), 164-173.
[http://dx.doi.org/10.1016/j.jchromb.2008.05.001] [PMID: 18502700]

Psychogios, N.; Hau, D.D.; Peng, J.; Guo, A.C.; Mandal, R.; Bouatra, S.; Sinelnikov, I.; Krishnamurthy, R.; Eisner, R.; Gautam, B.; Young, N.; Xia, J.; Knox, C.; Dong, E.; Huang, P.; Hollander, Z.; Pedersen, T.L.; Smith, S.R.; Bamforth, F.; Greiner, R.; McManus, B.; Newman, J.W.; Goodfriend, T.; Wishart, D.S. The human serum metabolome. PLoS One, 2011, 6(2), e16957.
[http://dx.doi.org/10.1371/journal.pone.0016957] [PMID: 21359215]

Bouatra, S.; Aziat, F.; Mandal, R.; Guo, A.C.; Wilson, M.R.; Knox, C.; Bjorndahl, T.C.; Krishnamurthy, R.; Saleem, F.; Liu, P.; Dame, Z.T.; Poelzer, J.; Huynh, J.; Yallou, F.S.; Psychogios, N.; Dong, E.; Bogumil, R.; Roehring, C.; Wishart, D.S. The human urine metabolome. PLoS One, 2013, 8(9), e73076.
[http://dx.doi.org/10.1371/journal.pone.0073076] [PMID: 24023812]

Karu, N.; Deng, L.; Slae, M.; Guo, A.C.; Sajed, T.; Huynh, H.; Wine, E.; Wishart, D.S. A review on human fecal metabolomics: Methods, applications and the human fecal metabolome database. Anal. Chim. Acta, 2018, 1030, 1-24.
[http://dx.doi.org/10.1016/j.aca.2018.05.031] [PMID: 30032758]

Huang, Q.; Tan, Y.; Yin, P.; Ye, G.; Gao, P.; Lu, X.; Wang, H.; Xu, G. Metabolic characterization of hepatocellular carcinoma using non-targeted tissue metabolomics. Cancer Res., 2013, 73(16), 4992-5002.
[http://dx.doi.org/10.1158/0008-5472.CAN-13-0308] [PMID: 23824744]

Liu, Y.; Hong, Z.; Tan, G.; Dong, X.; Yang, G.; Zhao, L.; Chen, X.; Zhu, Z.; Lou, Z.; Qian, B.; Zhang, G.; Chai, Y. NMR and LC/MS-based global metabolomics to identify serum biomarkers differentiating hepatocellular carcinoma from liver cirrhosis. Int. J. Cancer, 2014, 135(3), 658-668.
[http://dx.doi.org/10.1002/ijc.28706] [PMID: 24382646]

Fages, A.; Duarte-Salles, T.; Stepien, M.; Ferrari, P.; Fedirko, V.; Pontoizeau, C.; Trichopoulou, A.; Aleksandrova, K.; Tjønneland, A.; Olsen, A.; Clavel-Chapelon, F.; Boutron-Ruault, M.C.; Severi, G.; Kaaks, R.; Kuhn, T.; Floegel, A.; Boeing, H.; Lagiou, P.; Bamia, C.; Trichopoulos, D.; Palli, D.; Pala, V.; Panico, S.; Tumino, R.; Vineis, P.; Bueno-de-Mesquita, H.B.; Peeters, P.H.; Weiderpass, E.; Agudo, A.; Molina-Montes, E.; Huerta, J.M.; Ardanaz, E.; Dorronsoro, M.; Sjöberg, K.; Ohlsson, B.; Khaw, K.T.; Wareham, N.; Travis, R.C.; Schmidt, J.A.; Cross, A.; Gunter, M.; Riboli, E.; Scalbert, A.; Romieu, I.; Elena-Herrmann, B.; Jenab, M. Metabolomic profiles of hepatocellular carcinoma in a European prospective cohort. BMC Med., 2015, 13(1), 242.
[http://dx.doi.org/10.1186/s12916-015-0462-9] [PMID: 26399231]

Luo, P.; Yin, P.; Hua, R.; Tan, Y.; Li, Z.; Qiu, G.; Yin, Z.; Xie, X.; Wang, X.; Chen, W.; Zhou, L.; Wang, X.; Li, Y.; Chen, H.; Gao, L.; Lu, X.; Wu, T.; Wang, H.; Niu, J.; Xu, G.A. Large‐scale, multicenter serum metabolite biomarker identification study for the early detection of hepatocellular carcinoma. Hepatology, 2018, 67(2), 662-675.
[http://dx.doi.org/10.1002/hep.29561] [PMID: 28960374]

Han, J.; Qin, W.; Li, Z.; Xu, A.; Xing, H.; Wu, H.; Zhang, H.; Wang, M.; Li, C.; Liang, L.; Quan, B.; Yan, W.; Shen, F.; Wu, M.; Yang, T. Tissue and serum metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma. Clin. Chim. Acta, 2019, 488, 68-75.
[http://dx.doi.org/10.1016/j.cca.2018.10.039] [PMID: 30389456]

Zhou, P.C.; Sun, L.Q.; Shao, L.; Yi, L.Z.; Li, N.; Fan, X.G. Establishment of a pattern recognition metabolomics model for the diagnosis of hepatocellular carcinoma. World J. Gastroenterol., 2020, 26(31), 4607-4623.
[http://dx.doi.org/10.3748/wjg.v26.i31.4607] [PMID: 32884220]

Pan, H.Y.; Wu, Q.Q.; Yin, Q.Q.; Dai, Y.N.; Huang, Y.C.; Zheng, W.; Hui, T.C.; Chen, M.J.; Wang, M.S.; Zhang, J.J.; Huang, H.J.; Tong, Y.X. LC/MS-based global metabolomic identification of serum biomarkers differentiating hepatocellular carcinoma from chronic hepatitis B and liver cirrhosis. ACS Omega, 2021, 6(2), 1160-1170.
[http://dx.doi.org/10.1021/acsomega.0c04259] [PMID: 33490775]